



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Lab ID 24285101-001

Collect Dt/Tm 07/12/2024 08:45

Matrix Serum

Source Not Given

Patient Name WILLIAMS, DANIEL MARK

Patient ID Not Provided

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

Synonym(s): Perfluorooctane Sulfonamide

General U.S. population from CDC-NHANES (2011-2012) (n=1904) is typically below 0.10 ng/mL (95th percentile)

NASEM Summation Value

7.0

ng/mL

The National Academies of Science, Engineering, and Medicine (NASEM) recommends the following clinical guidance related to an additive sum value for MeFOSAA, PFHxS, PFOA (linear and branched isomers), PFDA, PFUnDA, PFOS (linear and branched isomers), and PFNA in serum or plasma:

- Adverse health effects related to PFAS exposure are not expected at less than 2 ng/mL.
- There is a potential for adverse effects, especially in sensitive populations, between 2 and 20 ng/mL.
- There is an increased risk of adverse effects at greater than 20 ng/mL.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.